Parallel Group, Randomised, Placebo Controlled, Double Blind Oral Assessment of OC000459 Dosed Twice Daily for 28 Days in Asthmatic Subjects.

Trial Profile

Parallel Group, Randomised, Placebo Controlled, Double Blind Oral Assessment of OC000459 Dosed Twice Daily for 28 Days in Asthmatic Subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jan 2012

At a glance

  • Drugs OC 459 (Primary)
  • Indications Asthma
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 01 Jan 2012 Results published in Clinical and Experimental Allergy.
    • 29 Jan 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health record NCT01057927).
    • 29 Jan 2010 Official title added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top